Avantor (AVTR) will face challenges in its primary markets and potential declines in channel shares in 2025, while its advantages including reduced exposure to the Chinese market and minimal reliance on instrument sales may diminish, UBS Securities said in a note on Friday.
The traditional strategy of mergers and acquisitions to boost growth is becoming less viable for Avantor due to rising target valuations and increased interest rates, and the company may find it difficult to pursue inorganic growth opportunities effectively, the firm added.
UBS said that despite optimism about a rebound in bioprocessing demand in 2025, Avantor's strengths lie more in-process materials and formulation chemicals, rather than in areas like downstream filtration, purification, and single-use consumables, where the most significant demand increases are expected.
The brokerage downgraded its rating on Avantor's stock to neutral from buy and decreased the price target to $25 from $29.
Price: 21.93, Change: -0.65, Percent Change: -2.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。